Understanding how protein structure relates to protein activity is a problem of fundamental importance in biology that is being studied from many directions. Members of the large superfamily of nuclear receptors provide compelling examples of how molecular biology, structural biology, biochemistry and modelling can combine to provide a progressively refined, molecular-level understanding of how this class of transcription factors work and, in particular, how many of them are regulated by ligands. The study of oestrogen receptor-α (ERα), in particular, has led the way in defining the roles played by the different domains of these nuclear receptors in their interaction with agonist and antagonist ligands and in (HSPs) (mainly HSP90) and is likely a monomer 4,5 (Fig. 1b) . When an agonist like oestradiol binds, the LBD sheds the HSPs, dimerizes and becomes stabilized in a conformation in which the last helix (h12) folds over the ligand-binding pocket (LBP), forming a hydrophobic groove into which co-activators bind (Fig. 1c) . By contrast, when an anti-oestrogen like tamoxifen binds to the LBD, its side chain prevents h12 from forming an active AF2 conformation. Thus, h12 docks in the AF2 hydrophobic groove and blocks co-activator binding (Fig. 1d) .
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When activated by oestrogen, ERα increases proliferation and progression of ERα-positive breast cancers, which constitute mostly the luminal A and luminal B breast cancer subtypes 6, 7 . Many of these breast cancers are effectively treated with aromatase inhibitors such as letrozole or with anti-oestrogen ligands of either the selective oestrogen receptor modulator (SERM) or selective oestrogen receptor downregulator (SERD) type, the mainstays of endocrine therapies. Recently, deep DNA sequencing has revealed activating mutations in the gene region encoding the LBD of ERα in about 40% of recurrent, ER-positive breast cancers 6, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] . Most of these mutations convey constitutive activity to levels approximating those achieved by hormone stimulation [14] [15] [16] [17] 22, 23, [26] [27] [28] . It is no surprise then that these mutations are strongly associated with the reduced efficacy of oestrogen-deprivation therapies such as aromatase inhibitors 9, 13, 23 and of some ER antagonists such as tamoxifen 12, 15, 17, 19, 22, 23 . Thus, these mutations establish the clinical need for developing more effective endocrine therapy agents or treatment combinations 3, 23, 29 , but they also provide opportunities for understanding how the structure of ERα, most notably the ligand-induced conformation of its LBD, is related to its activity.
In this Opinion, we discuss how these naturally occurring mutations in ERs have furthered our understanding of the molecular mechanisms involved in ER activation. By bringing together recent findings from X-ray crystallography, molecular dynamics modelling (MDM) and biophysical, biochemical and cellular assays, we present new insights into specific conformational constraints that work to ensure that the wild-type ER LBD is kept in an 'off-state' in the absence of oestrogen 12, 19, 30 . defining how these interactions translate into the regulation of transcription.
ERα is the main transcription factor regulating the biology of over 70% of human breast cancers [1] [2] [3] . ERα, like the androgen receptor (AR) and other members of the nuclear receptor superfamily, has a DNA-binding domain C (DBD), a ligand-binding domain E (LBD) and activation functions (AF1 in the aminoterminal A/B domain and AF2 in the LBD) that control transcription and hormonedependent gene expression (Fig. 1a) . The LBD of ERα (amino acids 304-554) consists of 12 α-helices (h1-h12) linked mostly by loop regions. In the absence of a bound ligand, this domain is inactive, likely partially disordered, bound by heat shock proteins Abstract | Oestrogen receptor-α (ERα), a key driver of breast cancer, normally requires oestrogen for activation. Mutations that constitutively activate ERα without the need for hormone binding are frequently found in endocrine-therapy-resistant breast cancer metastases and are associated with poor patient outcomes. The location of these mutations in the ER ligand-binding domain and their impact on receptor conformation suggest that they subvert distinct mechanisms that normally maintain the low basal state of wild-type ERα in the absence of hormone. Such mutations provide opportunities to probe fundamental issues underlying ligand-mediated control of ERα activity. Instructive contrasts between these ERα mutations and those that arise in the androgen receptor (AR) during anti-androgen treatment of prostate cancer highlight differences in how activation functions in ERs and AR control receptor activity , how hormonal pressures (deprivation versus antagonism) drive the selection of phenotypically different mutants, how altered protein conformations can reduce antagonist potency and how altered ligand-receptor contacts can invert the response that a receptor has to an agonist ligand versus an antagonist ligand. A deeper understanding of how ligand regulation of receptor conformation is linked to receptor function offers a conceptual framework for developing new anti-oestrogens that might be more effective in preventing and treating breast cancer.
When different components of these constraints become relieved by the various activating mutations, mutant ERα LBDs are able to refold into an agonist conformation without needing the stabilization provided by agonist ligand binding. Instructive contrasts can be made between these ERα-activating mutations in breast cancer and those observed in ARs in prostate cancer. Understanding the different mechanisms involved in mediating receptor activation informs a deeper appreciation of how ligand regulation of receptor conformation is linked to receptor function and provides a framework to guide the development of new anti-oestrogens that might be more effective in preventing and treating breast cancer.
ERα activating mutations
Constitutively active ERα mutants were first reported in the 1990s through structurefunction studies that employed random or site-directed mutagenesis of breast cancer cells with phenotypic selection in the absence of oestradiol or the presence of anti-oestrogens 26, 27, 31 . The first report of an activating mutation in ESR1, the gene encoding ERα, in a breast cancer metastasis also appeared in the 1990s 28 , but the clinical prevalence of these single nucleotide polymorphisms became evident only more recently as a result of technological advances that facilitated deep DNA sequencing of tumours 11, 32 . The prevalent, activating mutations are all located in the gene region encoding the ERα LBD and are found in three distinct zones ( Fig. 2 ; Supplementary Movie 1) (A compendium of ESR1 mutations can be found in the cBioPortal database of cancer mutations from more than 10,000 samples 33 ).
'The Importance of Being Off' Activating mutations in the gene region encoding the LBD occur at sites outside the LBP and therefore involve residues that are not directly in contact with the bound ligand. Hence, the question arises as to how mutations distributed at these three distinct, ligand-remote sites cause constitutive, ligand-independent activation of ERα. However, because a ligand-regulated transcription factor needs to be switched off in the absence of agonist binding so that its activity can be increased upon binding of an agonist, the proper question to ask is how each of these mutations is able to subvert several distinct mechanisms that enforce the off-state of unliganded wild-type ERα (the apo form of ERα, named wild-type apo-ERα). It is really by recognizing 'The Importance of Being Off ' (adapted from the 1895 Oscar Wilde play The Importance of Being Earnest
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) that we can begin to understand how each of these mutations undermines several distinct mechanisms that enforce the off-state of wild-type apo-ERα.
We use the term 'off ' to characterize the inability of wild-type apo-ERα to enhance breast cancer proliferation and progression. In the absence of a ligand, wild-type ERα and other nuclear receptor superfamily members are predominantly bound by HSPs 4 , an interaction that protects these receptors from proteolysis and from which they can be released in an active form by ligand binding. Even without a ligand, however, wild-type ERα may still function, which often occurs as a result of post-translational modifications 35, 36 in response to other growth-regulating signalling systems, such as epidermal or insulin-like growth factors [37] [38] [39] [40] . Additionally, associated and interacting factors, such as co-regulators, modifiers of the epigenome, post-translational modifications, cell signalling pathways and other transcription factors including other nuclear receptors and the ERβ subtype 41, 42 , can modify the response to hormone deprivation and antioestrogen treatments and lead to ligandindependent activation in breast cancer, even in the absence of ERα-activating mutations. However, mutations leading to constitutively active ERα are responsible for the highest percentage, upwards of 35-40%, of therapy resistance [8] [9] [10] . 
Zones of activating mutations
The prevalent, activating mutations in ESR1 are all located in the gene region encoding the LBD, and they are found in three distinct zones ( Fig. 2; Supplementary Movie 1) . Notably, their activating effects are directed at distinct mechanisms by which the offstate of wild-type apo-ERα is enforced. To keep track of these mechanisms, we have designated the three zones of mutant interactions with functional terms: 'the spring' (zone 1), 'the charge repulsion' (zone 2) and 'the instability' (zone 3) (Fig. 2) .
Zone 1 -the spring Loops in protein structures are typically thought of as flexible and often unstructured turn regions with no function beyond that needed to connect the ends of nearby secondary structural elements. The h11-h12 loop in wild-type ERα, by contrast, appears to provide a critical function in keeping wild-type apo-ERα off. Several lines of evidence (X-ray crystallography, MDM and deuterium exchange kinetics) suggest that when h12 bends over the LBP to adopt the active conformation (Fig. 1c) , the h11-h12 loop experiences an inherent spring-like strain owing to the aqueous exposure of consecutive hydrophobic residues (V533, V534, P535 and L536) in its sequence 12 .
Wild-type ERα requires the energy from binding an agonist ligand to bend this spring into the strained agonist conformation. In the absence of a bound ligand, the springlike nature of the h11-h12 loop ensures that this domain retains some degree of disorder 43 ( Fig. 1b) . This intrinsic disorder is likely the reason for the binding of wild-type apo-ERα to HSPs 4 , for the great ease with which proteases can cut in the h11-h12 loop 44 and for the lack of success in crystallizing the wild-type LBD unless it has bound a ligand 30 . These springlike properties are markedly changed by mutations in this loop 12, 30 . Y537S, Y537N and Y537C -latching the h11-h12 spring with a stronger hydrogen bond. Among the ERα mutants identified in endocrine-therapy-resistant disease, the Y537 site is the one most frequently mutated 8, 9, 23 . Cell activity assays show that the Y537S mutation enables nearly full constitutive activity and reduces antioestrogen potencies, and the penetrance of these characteristics is reduced in Y537N mutants and particularly in Y537C mutants 23 ( Fig. 2b) . Recently identified in one patient, ERα-Y537D is a constitutively active mutant as well 23 . Other residues introduced at the Y537 site by site-directed mutagenesis (Y537A, Y537E, Y537F and Y537K) confer generally lower levels of constitutive activity than those of the clinically reported Y537D; of these, only Y537F can occur through a single nucleotide change 27, 45, 46 , yet thus far it has not been reported clinically, and its relevance in breast cancer is therefore unclear.
The growing corpus of crystal structures obtained for the Y537S mutant clearly shows that h12 is in the agonist conformation 12, 30, 47, 48 , even without a bound ligand 30 . The hydrogen-bonding partner of S537 in the Y537S mutant is D351 on h3, and this tight interaction appears to 'latch' the h11-h12 spring in the agonist conformation, turning on constitutive activity. This S537-D351 interaction in the mutant ERα appears more highly optimized than the Y537-N548 interaction in wild-type ERα, which is predicted from MDM 12 . In addition to its strong latching hydrogen bond with D351, the Y537S mutation also enables a more optimal packing of the three hydrophobic side chains 12 . Of note, phosphorylation of the Y537 site by the tyrosine kinase c-SRC upregulates ERα cellular activity and alters its subcellular distribution 49 . D538G -lengthening the h11-h12 spring by unwinding h12. The D538G mutation, in the h11-h12 loop of the ERα LBD, is observed in ~20% of patients with aromatase inhibitor-treated metastatic breast cancer [8] [9] [10] 14 and confers constitutive activity comparable to that of Y537S 18, 21, 23, 50 (Fig. 2b) .
Structural data show that the charged D538 residue in wild-type apo-ERα introduces a kink in the protein backbone driven by its strong preference for solvent exposure and electrostatic repulsion from other nearby acidic residues (for example, D351) and that it initiates the helical character at the start of h12 (reF.
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). The D538G mutation, which is the single mutation most commonly found in the clinic 12, 24 , eliminates the electrostatic components and, coupled with the glycine 'helix-breaking' backbone conformational preferences, results in a change in loop conformation that erodes the beginning of h12 from amino acid 538 to 539. This 'lengthening' of the h11-h12 spring in ERα-D538G enables better side chain packing for the hydrophobic residues. Curiously, these changes also disrupt the canonical hydrogen bond presumed to form between Y537 and N348 in the wild-type LBD 12 . MDM simulations had predicted that the D538G mutation led to the loss of this interaction and indicated that Y537 in wild-type ERα adopts multiple orientations of its side chain, which was then confirmed by X-ray crystal structures 12 . Other synthetic mutations were explored at this site (D358A, D358N and D358V), but none of these were found to confer constitutive activity 22, 46, 51 , suggesting that the unique flexibility afforded by D538G is essential for lengthening the spring.
L536R, L536H, L536P and L536Q -softening the h11-h12 spring by reducing hydrophobicity. Of the h11-h12 mutations, mutations at L536 are found less often than others (~1% of patients with aromatase inhibitor-treated metastatic breast cancers) 9, 23 , and they convey relatively modest constitutive activity 23 ( Fig. 2b) .
Nevertheless, in cell-based assays, the constitutive activity conveyed by the L536R mutation cannot be fully suppressed by anti-oestrogens, suggesting that this residue contributes in a major way to the h11-h12 loop strain in the wild-type sequence. Although no X-ray crystal structures are yet available for mutations at this site, L536 is observed in a solvent-exposed conformation in the majority of wild-type ERα LBD structures (21 out of 26 monomers in wildtype ERα LBD crystal structures have L536 exposed). This observation, when put into the context of structural changes observed in the h11-h12 loop owing to the mutations described above, suggests that the alteration of L536 from strongly hydrophobic to charged (L536R), polar (L536H and L536Q) or less hydrophobic (L536P) enables a more energetically optimal arrangement of the remaining hydrophobic side chains (that is, amino acids 533-535), in essence 'softening' the h11-h12 spring.
Fortuitously, support for this hydrophobic-exposure mechanism can be ascertained by comparing the h11-h12 loops in both ERα and ERβ. Both have identical loop sequences, except in place of a hydrophobic leucine residue at the 536 site in ERα, there is a less hydrophobic valine residue at the corresponding 487 site in ERβ (Supplementary Fig. 1a ). Likely owing to this difference, ERβ has a higher constitutive activity than ERα 52, 53 . The binding of the steroid receptor co-activator protein 3 (SRC3; also known as NCOA3) nuclear receptor interaction domain to apo-ERα can be used as a measure of constitutive activity 12, 53 . Consistent with the lack of constitutive activity in apo-ERα, fluorescence resonance energy transfer assays demonstrated that there was no binding of SRC3 to apo-ERα 53 ( Supplementary Fig. 1b) , whereas there was strong binding to wild-type apo-ERβ ( Supplementary Fig. 1c ) consistent with its substantial constitutive activity 53 and comparable to the SRC3 binding found in some constitutively active ERα mutants 12, 27, 31 . While the two ER subtypes differ in sequence in regions outside of the h11-h12 loop, this site-specific comparison within the h11-h12 loop suggests that exposure of a hydrophobic residue at the 536 position in ERα is a major contributor to the strength of the h11-h12 spring in keeping wild-type apo-ERα off, with the L536 in ERα giving a stronger 'turn-off spring' mechanism than the corresponding V487 in ERβ. A number of other synthetically introduced residues at 536 (such as L536A, L536I, L536E, L536G, L536K and L536N) are also less hydrophobic than L536 and convey some constitutive activity 46, 54 , but of these, only L536I can occur through a single nucleotide change; however, it has not been reported clinically, and its relevance in breast cancer is unclear.
Zone 2 -the charge repulsion
Among the ERα mutants identified in endocrine-therapy-resistant disease, E380 is the third most frequently mutated residue (~5% of patients with aromatase inhibitortreated metastatic breast cancers) 9 . In cell-based assays, it has been shown that mutations at E380 convey modest levels of constitutive activity and resistance to anti-oestrogens 26 ( Fig. 2b) , although clinical resistance in patients carrying ERα-E380Q can be considerable 55 . Despite the lack of structural information for this mutant, one can formulate a plausible mechanism by which ERα activity might be engendered by a change from the acidic, negatively charged glutamic acid residue to a neutral residue, such as glutamine.
E380Q -neutralizing the charge repulsion.
Unlike the zone 1 mutations, which are immediately downstream in sequence from h12 and thus in position to affect its orientation directly, the E380 residue is in h5, very far in sequence from the start of h12 ( Supplementary Fig. 2 ). Nevertheless, E380 is close in space to the carboxy-terminal portion of h12, and from this position, there is likely a repulsion between the acidic, negatively charged E380 residue and the two acidic, negatively charged residues E542 and D545 in the middle of h12, an arrangement that disfavours h12 positioning in the active agonist conformation. The E380Q mutation would eliminate this charge repulsion interaction, enabling the active conformation to be achieved without the energy provided by agonist ligand binding. This is supported by a report showing that the synthetic ERα-E542K mutant, which would have a charge attraction interaction, has constitutive activity 46 . In addition, an E542G mutation, which would also reduce coulombic repulsion, was found in a patient with recurrent breast cancer 33 .
Zone 3 -the instability
The S463P mutation, observed in ~2% patients with aromatase inhibitor-treated metastatic breast cancer 9 , is curious in two respects: it has relatively low constitutive activity in reporter gene assays and resistance to antagonists in cells, yet clinically, it drives oestrogen-independent tumour growth in a manner similar to that resulting from mutations such as Y537S or D538G 22, 23 . Notably, of all the bestcharacterized mutations, S463P is most remote both in sequence and in space from h12 ( Fig. 2a; Supplementary Movie 1) . As with E380Q, there is no published structural information on ERα-S463P; therefore, statements on how this mutation conveys constitutive activity based on structural changes are speculative. (Fig. 2a) . In crystal structures of the wildtype ERα LBD, this loop is absent, suggesting that it is unstructured, which is consistent with the avidity with which this region is cleaved by proteases 44 . If the intrinsic disorder of this loop was one of the factors keeping wild-type apo-ERα bound to HSPs, then replacement of the serine residue with the structurally more constrained proline residue might counteract this intrinsic disorder and activate the LBD by favouring its release from HSPs. Because this loop is close to the dimer interface (Fig. 1c,d) , the S463P mutation could also affect the stability of ERα LBD dimers. Although not well understood, there are intriguing mechanisms by which the S463P mutation could affect the structure and function of the ERα LBD and alter the dimer interface (Box 1).
S463P -various modes
While this Opinion is focused on the most frequently observed mutations detailed above, the identification of additional mutations in the gene region encoding ERα LBD from breast tumour biopsy samples is an ongoing activity. Some more recently identified mutations are V422del, which is observed more often than S463P, is weakly activating 23 and is located at the start of h8
(close to but pointing away from the LBP); S432L, which is located in the middle of h8 but far from the LBP and is found in tamoxifen-treated patients but lacks activity in the absence of oestradiol 23 ; G442R, which is found at low frequency, conveys constitutive activity and is located at the start of h9 (far from the LBP) 23 ; and L469V, which is a conservative mutation that conveys considerable constitutive activity and is located at the start of h10 (far from the LBP but close to the dimer interface) 23 . At present, there are no plausible structural bases to account for the activity of these ERα mutants.
Anti-oestrogen resistance
We have detailed how wild-type ERα is able to maintain an off-state by relying on several structural features that prevent the LBD from folding into the agonist conformation when no ligand is bound. Intriguingly, it is this unfolded state of the wild-type ERα LBD that enables it to bind both agonist and antagonist ligands with particularly high affinities. Activating mutations that counteract the LBD off-state and enable it to fold without a ligand, however, reduce the binding affinities of both agonist and antagonist ligands and lead to anti-oestrogen resistance through mechanisms discussed below.
Intrinsic disorder and binding
Intrinsic disorder affords two components of ligand-binding energy. In biophysical studies probing the dynamics of the ERα LBD with fluorescent probes, the LBD in wild-type ERα was found to readily adopt a molten globule or intrinsically disordered state 43 . Intrinsic disorder is, in fact, a well-recognized, functional feature of binding proteins such as nuclear receptors 56 . These intrinsically disordered domains can open and close spontaneously, enabling them to search for their binding partners efficiently, an activity aptly termed 'fly casting' (reFs 57, 58 ). In addition, when intrinsically disordered protein domains interact with their binding partners, they gain two components of energy from new proteinligand contacts and also from new proteinprotein contacts that form in the more fully folded protein-ligand complex 59 . In the case of nuclear receptors like ERα, in which agonist ligands become completely engulfed by the protein but ligand-protein contacts are moderately sparse 60, 61 , the binding energy contribution from new protein-protein contacts must be considerable.
Pre-folding bias reduces ligand-binding energy. Activating mutations enable the ERα LBD to pre-fold into the agonist conformation without a ligand (Fig. 3a) . One can presume that this mutation-induced pre-folding will eliminate much of the second component of ligand-binding energy, the component that is derived from new protein-protein contacts that develop from folding the intrinsically disordered wildtype ERα LBD around the ligand. Loss of this folding energy will reduce the binding affinity of agonist ligands like oestradiol but will reduce the binding affinity of antioestrogens to a greater extent. The bias of mutant ERα to pre-fold into the agonist conformation means that additional energy is required by these mutants to access the antagonist conformation needed to bind the anti-oestrogens.
Constitutively active ERα mutants have reduced affinity for ligands.
We and others have measured the binding of oestradiol and several SERMs and SERDs to constitutively active ERα mutants by competitive radiometric and other binding assays 12, 19, 29, 50 , and results from our studies are summarized in Fig. 3b . Relative to wild-type ERα, the binding of both oestradiol and antagonists to the mutants is substantially reduced in most cases, with anti-oestrogen affinities being reduced to a greater extent (up to 60-fold) than those of oestradiol (up to 11-fold) 12 . Notably, the reduction in binding affinity parallels the level of mutant constitutive activity: Y537S, D538G and L536R all have similar binding affinities and activity levels, whereas E380Q has lower levels 23 , which can be considered a rough measure of the extent of pre-folding into the agonist conformation.
Box 1 | The role of the F domain
oestrogen receptors (eRs) are unique among the members of the nuclear receptor superfamily in having a substantial F domain (Fig. 1a) . The structure of the 40 carboxy-terminal residues (556-595) that constitute the F domain in full-length eRα has been difficult to study because eRα ligandbinding domain (lBD) crystal structures end abruptly around R555, which is another site of active protease cleavage considered to be the end of helix 12 (h12) and the e domain 44, 119 . Nevertheless, the function of the F domain is clearly important, as F domain mutations and truncations alter the balance of agonistic versus antagonistic properties of different ligands and increase the stability of eR dimers [120] [121] [122] [123] . In crystal structures of eRα lBD agonist dimers, the end of h12 is aimed at the dimer interface and appears to interfere with dimer stability (Fig. 1c) . eRα lBD agonist dimers are less stable than antagonist dimers, in which the end of h12 is directed away from the dimer interface 124 (Fig. 1d) .
Some idea of what might be happening to the dimer interface can be gleaned from the androgen receptor (AR) and other members of the glucocorticoid receptor subfamily. For example, AR proteins lack a comparable F domain but still have a few residues that extend beyond the site corresponding to R555 in eRα, which are visible in crystal structures (see Supplementary movies 2,3, and legends). These extended sequences form a β-sheet structure with the h9-h10 loop and eventually interact with residues in the usual dimerization zone, blocking or altering dimerization of the AR lBD 125 . The dimerization of full-length wild-type eRα might be similarly weakened by sequences at the start of the F domain through β-sheet interaction with the intrinsically disordered h9-h10 loop. Substitution of serine with the more structured proline in the S463P mutant might disfavour this β-sheet formation; by reducing interference with the dimer interface, the mutation could stabilize and activate eRs by minimizing their interaction with heat shock proteins. These mutations have a general or coordinate effect on the binding of not one but all antioestrogens (in marked contrast to mutations conferring endocrine-therapy-resistance in AR, see below). The markedly reduced binding affinity of antagonists to these ERα mutants is likely a major factor underlying their resistance to anti-oestrogens.
Comparing AR and ERα mutants
While we have thus far focused on how mutations in ESR1 can undermine the therapeutic benefit from aromatase inhibitors and anti-oestrogens in breast cancer, instructive comparisons can be made between the resultant ERα mutants and AR mutants when prostate cancer becomes resistant to anti-androgens. The sequence of endocrine therapies for prostate cancer roughly parallels that for breast cancer: when the disease becomes resistant to androgendeprivation therapy (through suppression of gonadal androgen biosynthesis) and progresses to the castration-resistant stage, therapy is changed to complete AR blockade, which involves the additional use of anti-androgens such as flutamide, bicalutamide or enzalutamide or systemic inhibitors of androgen biosynthesis such as abiraterone 62 . Despite this more intensive anti-androgen therapy, further resistance can develop as a result of mutations in the gene region encoding the AR LBD [62] [63] [64] [65] [66] [67] [68] . The nature of these therapy-resistancemediating mutations in the genes encoding AR and ERα, however, reflects inherent differences in the strength of the activation functions of the two receptors, the selection conditions under which the mutations arise and the location of the mutations and their pharmacological phenotype. These differences (summarized in TaBle 1 ) raise a cautionary note because they suggest that, when patients with breast cancer are treated initially and/or predominantly with antioestrogens rather than aromatase inhibitors, a different class of therapy-resistancemediating mutations might arise in ERα, an issue discussed below.
Carboxy-terminal-truncated AR mutants
AR can become constitutively active through C-terminal truncations. By contrast, ERα requires mutations in the gene region encoding the LBD to become constitutively active. This reflects contrasting ways by which these receptors use their two activation functions, AF1 in the N-terminal A/B domain and AF2 in the LBD (Fig. 1a) . The large AF1 in AR has intrinsic activity sufficient to drive proliferation in prostate cancer without the need for agonist binding. However, in the absence of ligands, AF2 in AR blocks AF1 activity. Hence, C-terminal truncation of the AR LBD removes the inhibitory effect of AF2 and produces a constitutively active AR mutant 69 . By contrast, AF1 in ERs is smaller and requires contributions from AF2 activated by agonist binding to drive proliferation in breast cancer. Consequently, constitutive activity in ERs arises from mutations in the gene region encoding the LBD that activate AF2 in the absence of a ligand. It is of note that a translocation between YES-associated protein 1 (YAP1) and ESR1 found in an ERα-positive breast cancer metastasis results in a gene product in which the ERα LBD has been removed by a C-terminal truncation 12, 19 . AE binding was determined by a competitive binding assay using [ . Because the half-maximal inhibitory concentration values from the competition assay are affected by the E 2 binding affinities, they have been converted to K i values using the Cheng-Prusoff relationship 126 . (Data on WT, Y537S and D538G ERα LBDs for E 2 , hydroxytamoxifen and fulvestrant are updated values with more replicates from our published work 12, 50 ; the values for the other ERα mutants and for raloxifene and bazedoxifene were determined in our laboratories using the same published methodology 12, 19, 50 ).
and a ligand-independent YAP1 activation sequence has been added. This fusion protein is constitutively active and fully insensitive to fulvestrant 15 and thus is phenotypically similar to the C-terminal-truncated ARs.
Location of AR and ERα gene mutations
The activating mutations in ESR1 result in amino acid changes that are all outside of the LBP and thus are not in direct contact with a ligand (Fig. 2a; Supplementary  Movie 1) . By contrast, mutations in the gene encoding AR that convey resistance to antiandrogens result in amino acid changes that are inside the LBP (Supplementary Movies  2,3 ) and in direct contact with antagonist ligands (Fig. 4) . In addition, ERα mutations arise predominantly during endocrine deprivation (aromatase inhibitor treatment) and convey constitutive activity as well as resistance to anti-oestrogens, which results in lowered general antagonist affinity and potency (Fig. 3b) . By contrast, AR mutations arise under androgen-antagonist-selective conditions and affect different antagonists in compound-specific ways 62 (TaBle 1; Fig. 4b ).
AR-activity-inversion mutants
Mutations in the gene region encoding the AR LBD prevent anti-androgens from inducing an antagonist conformation. They are located at characteristic sites where certain residues interact strongly with a portion of an individual anti-androgen (Fig. 4a) , and the mutational change reduces the size or increases the flexibility of these contact residues. This reduces the steric strain through which the anti-androgen is thought to distort the AR LBD into an antagonist conformation (Fig. 4b) , with the net result that the respective anti-androgen becomes an agonist. In fact, increasing the size of the anti-androgen substituent juxtaposed to the smaller-sized residue in the AR mutant appears to be a viable strategy for designing analogues, having restored anti-androgen activity against these specific AR mutant proteins 70, 71 . Detailed analyses of antagonist ligand binding to AR are limited because, unlike for the ERα LBD, there are no crystal structures available for the AR LBD in complex with an antagonist. Therefore, structures illustrating complexes with anti-androgens ( Fig. 4a; Supplementary Movies 2,3) are derived from modelling based on agonist conformations 72 . Nevertheless, resistancemediating mutations in the gene encoding AR can be classified as 'ligand-activityinversion mutations' because they change the receptor's interpretation of the ligand from an antagonist to an agonist.
ERα-activity-inversion mutants
Activating mutations in ESR1 that arise under conditions of oestrogen deprivation also convey reduced sensitivity of ERα to anti-oestrogens because of the pre-folding bias towards the agonist conformation in the respective ERα mutants (Fig. 3) . However, in contrast to activating mutations in the gene encoding AR, activating mutations in the gene encoding ERα do not make anti-oestrogens function as agonists or prevent high doses of anti-oestrogens from inducing an antagonist conformation. Could a different type of ERα mutant with ligandactivity-inversion character, as seen in AR mutants, arise in patients with breast cancer treated solely with anti-oestrogens? An informative prospect is ERα-L540Q, which was identified in early ERα mutagenesis studies when selection was done in the presence of anti-oestrogens 51, [73] [74] [75] [76] . The L540Q mutant is substantially activated by the anti-oestrogens hydroxytamoxifen, ICI164384 and RU54876 (akin to the antiandrogen activation of AR mutants), but ERα-L540Q also functions as a dominantnegative mutant: it is neither active in the absence of ligand nor in the presence of oestradiol and functions under these conditions as a potent suppressor of wild-type ERα activity [73] [74] [75] . Remarkably, a careful search of available clinical databases identified one patient who presented with a metastasis harbouring this L540Q mutation after 5 years of tamoxifen-only therapy (S. Chandarlapaty, unpublished observations). While the L540Q mutation has not yet been reported elsewhere, there has been limited reporting of deep sequencing of the gene encoding ERα in recurrent disease after exposure to ER antagonists alone. This mutation would not arise under oestrogen deprivation by aromatase inhibitors because its dominantnegative activity would inhibit wild-type ERα function and actually suppress, not stimulate, proliferation. In fact, if an L540Q mutation were to arise in a patient being treated with an anti-oestrogen, withdrawal of the drug might cause marked regression because of the dominant-negative effect of the unoccupied ERα-L540Q [73] [74] [75] . The effect of the L540Q substitution in ERα resembles effects of mutations in the gene region encoding the AR LBD because it mediates the ligand-activity-inversion character, but it differs from them because it does not convey resistance to specific antagonists rather than to antagonists in general. The L540Q change places a polar residue in the middle of h12, which probably prevents it from adopting either the agonist or the antagonist conformation (Fig. 1c,d ). Of interest, synthetic mutations of other hydrophobic residues in h12 also lead to this type of ligand-activity-inversion character 77 . Hence, the molecular mechanisms by which ERα-L540Q and related h12 mutations function deserve further study.
ERα LBD amino acid substitutions at two other sites convey an increased agonist response to SERMs. The first mutation, D351Y, was identified in an MCF-7 tumour xenograft mouse model found to be therapy resistant when treated with tamoxifen 78, 79 . As for L540Q, a variety of SERMs have substantial partial agonist activity on ERα-D351Y in transcription assays 80 ; however, unlike ERα-L540Q, the SERD fulvestrant remains a full antagonist and oestradiol remains a full agonist [81] [82] [83] . D351 is an acidic residue in the middle of h3, close to the side chains of anti-oestrogens, and appears to have an important attractive interaction with the basic side chains of certain SERMs (for example, tamoxifen and raloxifene) 60, 61, 84 and a repulsive interaction with the acidic side chain of other ER antagonists (for example, GW-5638 and AZD-9496) 83, 85, 86 . Both of these interactions would be abrogated by replacement of the negatively charged aspartate with the uncharged tyrosine. The second mutation, G400V, was identified during the initial cloning of ERα 87 ; in cells, it too conveys a more agonistic response to some SERMs 88 but not to SERDs [89] [90] [91] . G400 is located far from the LBP, at the start of the β-sheet region following h6; as such, there is no clear molecular basis for these behaviours. Unlike ERα-L540Q, neither of these ERα mutations has yet been found in breast cancer sequencing databases.
Drug design
From processes described so far, one can advance some general considerations about how endocrine therapies for breast cancer might be improved. One can also appreciate the critical importance of sharing the lessons learned from ESR1 mutations in breast cancer and AR mutations in prostate cancer in formulating the most beneficial and durable endocrine therapy strategies for each of these cancers.
Even though constitutively active ERα mutants have reduced sensitivity to ERα antagonists, the proliferative drive of these mutants can still be overcome with higher concentrations of current antioestrogens, although the dose required differs depending on the mutation 23, 50 . Thus, a strategy already underway is the improvement of pharmacokinetic properties to increase the exposure of tumours to highly potent antagonists. Some emerging orally active anti-oestrogens, such as AZD-9496 and GDC-0810 as well as others, appear to show encouraging behaviour 29, 50, [92] [93] [94] [95] [96] [97] [98] [99] [100] , although further studies are needed regarding side-effect profiles and long-term prevention of disease recurrence.
While most anti-oestrogens appear to block ER activity largely by a direct mechanism through which the antioestrogen side chain repositions h12 from the agonist conformation into an antagonist conformation (Fig. 1d) , surprisingly few ligand structural strategies have been explored to accomplish this, with most anti-oestrogens having either a basic amine as in tamoxifen and raloxifene 101, 102 , an acrylic acid side chain as in AZD-9496 and GDC-0810 (reFs 29, 85, 93 ) or a long, extended, largely hydrophobic chain as in ICI182780 (fulvestrant) 103 and RU58668
(reF.
104
). Other side chain design strategies could be evaluated, as could the optimal matching between anti-oestrogen side [62] [63] [64] [65] [66] [67] [68] . Because hydroxyflutamide and nilutamide have similar structures, similar sites of mutation are associated with resistance to these anti-androgens; the W742C and/or W742L site conveying resistance to bicalutamide is not shown in this perspective. Associations are indicated by check marks. While nominally a blocker of androgen biosynthesis from adrenal precursors, abiraterone and particularly its oxidized metabolite D4A are also direct AR antagonist ligands 127, 128 . Abiraterone therapy also elevates levels of pro-gestational ligands and suppresses corticosteroid production, necessitating corticosteroid supplementation. These AR mutants have reduced AR binding specificity and are activated by progestins and corticosteroids 129 . h, helix.
chains and core structural elements, with the goal of optimizing affinity, potency and anti-proliferative effectiveness while also seeking the best pharmacokinetic behaviour. There are even alternative approaches to disrupting the ERα agonist conformation by indirect mechanisms using ligands with expanded core elements (even ones without side chains) that distort the positioning of regions within the LBP that are needed to support the agonist conformation of h12 (reFs 48, [105] [106] [107] ). Finally, it will also be important to clarify the necessity of coupling ERα antagonism with ERα degradation (SERD activity) and determine whether ERα levels of both wild-type and mutant ERs can be lowered sufficiently to achieve reduced breast cancer progression. ER-degrading compounds of more explicit design, termed protease-targeting chimaeras (PROTACs), pair an ER ligand with a degron moiety that directs the ER-PROTAC complex to specific E3 ligases for proteasomal degradation 108 . Also, though beyond the scope of this Opinion, there are other types of therapies that can modulate ER expression (epigenetic strategies) 109 or ER activity (inhibitors of post-translational modifications 110 , coregulators 111 or bromodomain and extra-terminal motif (BET) inhibitors 112 ).
Resistance mutation screening
Although ERα mutants appear to be uniformly less sensitive to multiple antioestrogens, it is possible that a broader exploration of modes of anti-oestrogen action might lead to antagonists that are efficacious when specific mutations are present. In any case, the clinical exploration of structurally novel anti-oestrogens or new endocrine therapy strategies should be coupled with forward-looking mutagenesis studies to explore new ERα alterations by which resistance might develop. By getting ahead of potential limitations to the durability of their clinical effectiveness, drug development could explore structural modifications that might overcome the resistance due to these specific new mutations in advance of their appearance in the clinic. Thus far, this has been done more extensively with new anti-androgens 70, 113 , but the early generation 51, [73] [74] [75] [76] and recent clinical observation of the ERα-L540Q ligand-activity-inversion mutation after exposure to tamoxifen (see above) and the finding of other ERα-activity-inversion mutations [78] [79] [80] [81] [82] [83] [87] [88] [89] [90] [91] suggest that resistance to any structurally new anti-oestrogens through ERα LBD mutation should be screened for proactively. The general trend to combine anti-oestrogen endocrine therapies with other targeted-therapy agents, such as cyclin-dependent kinase 4 (CDK4) and/or CDK6 inhibitors as well as other agents, may minimize the risk from different modes of therapy resistance 42, [114] [115] [116] [117] [118] , including those due to mutations in ESR1.
Conclusions
In this Opinion, we have presented our current understanding of how activating mutations in the gene region encoding ERα LBD contribute to endocrine therapy resistance in breast cancer, highlighting the molecular mechanisms by which they undermine the varied structural features of wild-type ERα that ensure it is off in the absence of oestrogens ('The Importance of Being Off '). Metastatic, therapy-resistant breast cancers that arise due to ESR1 mutations are a substantial medical issue and the cause of many deaths 8 . Therefore, a deeper understanding of the molecular mechanisms by which mutant ERα proteins generate hormone-independent, constitutive and antagonist-resistant activities should facilitate the development of a toolbox of anti-oestrogens to overcome this 'on-state' of the receptor so as to improve endocrine therapies of breast cancer for patients now and in the future.
Glossary
Activation functions regions of amino acid sequence or 3D structure in transcription factors that are associated with the activation of transcription.
Androgen receptor
(ar). a transcription factor that is a member of the nuclear hormone receptor superfamily. it is the principal mediator of the biological effects of androgens and a major driver of the proliferation and progression of prostate cancer.
Anti-oestrogen
a ligand for the oestrogen receptor (er) used as one form of endocrine therapy for breast cancer. antioestrogens bind to er and alter its conformation so that it is unable to stimulate the proliferation and progression of breast cancer cells.
Apo a term that indicates that a binding protein is in its unliganded state.
Aromatase inhibitors
Used as a form of endocrine therapy for breast cancer that works by blocking the production of oestrogens by the ovaries and other tissues, such as the adrenals, and by the tumour itself.
Conservative mutation
The replacement of a residue in a protein with one that has similar physical properties.
Coulombic repulsion
a force separating two entities of equal charge, either positive-positive or negative-negative, when they are close in space.
Heat shock proteins (HsPs). a family of proteins that selectively bind other proteins that are intrinsically or aberrantly unfolded. HsP90 is the major protein to which wild-type apo-erα binds, although other HsPs also likely participate in this binding.
Ligand-binding domain
(lBD). a domain of the oestrogen receptor (er) responsible for binding oestrogens and anti-oestrogens. it is domain e out of the domains a-F and stretches approximately from amino acid 304 to 554 out of a total of 595 amino acids, accounting for about 40% of the overall length of erα. it is composed of 12 α-helices and a few β-strand elements that make up the secondary structure.
Ligand-binding pocket (lBP) . an interior region of the ligand-binding domain within which both agonist and antagonist ligands bind, with occasional portions of the ligands extending beyond the confines of the pocket.
Molecular dynamics modelling
(MDM). a computationally intensive method for exploring the conformation and dynamic features of proteins by providing alternating inputs of velocity on individual atoms and relaxation within the energy force field confines of the protein.
Nuclear receptors a superfamily of proteins of which the oestrogen receptor-α (erα) and the androgen receptor (ar) are members. Most members of the superfamily function largely as transcription factors, many of which are regulated by the binding of ligands, which can be endogenous metabolites (hormones) or exogenous ligands (pharmaceuticals, xenobiotics and so on).
Oestrogen receptor-α (erα). a transcription factor that is a member of the nuclear hormone receptor superfamily. The erα subtype is the principal mediator of the biological effects of oestrogens and a major driver of the proliferation and progression of breast cancer. erα is distinguished from another er subtype, erβ, which has very different biological activities that are largely unrelated to driving breast cancer progression.
Oestradiol a steroid with an aromatic a ring that is the principal endogenous oestrogen hormone that drives the proliferation and progression of breast cancer cells.
Selective oestrogen receptor modulator
(serM). a class of oestrogen receptor-α (erα) ligands that can have tissue-selective pharmacological effects, acting as agonists in some tissues (such as bone and vascular tissues) and antagonists in others (such as breast and uterine tissues). serMs such as tamoxifen are used in breast cancer endocrine therapy; other serMs such as raloxifene are used in hormone replacement therapies to protect bone in postmenopausal women.
Selective oestrogen receptor downregulator
(serD). a class of oestrogen receptor-α (erα) ligands such as fulvestrant that cause a reduction in the levels of the erα protein; they also function as er antagonists and are used in breast cancer endocrine therapies.
